30 results
Thumbnail

D1.391 - Pharmacist-led Risk-based β-Lactam Challenges in Patients with Penicillin Allergy: Impact on Antibiotic Days

Thumbnail

D1.379 - Six-year data evaluating the results of skin tests and provocation tests with quinolones in patients with a history of quinolone allergy

Thumbnail

D1.380 - Hypersensitivity reactions with proton pump inhibitors: five years of clinical experience

Thumbnail

D1.381 - Antibiotic Allergy De-labelling in Children: Outcomes of Drug Provocation Testing and Feasibility of Non-Specialist Pathways to de-labelling

Thumbnail

D1.382 - Vitamin K–Induced Anaphylaxis: A Case Series from a Tertiary Hospital in Manila, Philippines (2024–2025)

Thumbnail

D1.384 - Safe Sulfonamide Delabeling in HIV-Negative Adults: Real-World Evidence with TMP-SMX Oral Challenge and SULF-FAST

Thumbnail

D1.385 - Lamotrigine-induced Stevens-Johnson syndrome in a pediatric patient with Takayasu arteritis: the steroid paradox

Thumbnail

D1.386 - Adverse infusion reactions to biologicals in the treatment of inflammatory bowel diseases

Thumbnail

D1.387 - Long-term Follow-up Outcomes of Patients Undergoing Desensitization for Non-Immediate Hypersensitivity Reactions Associated with Lenalidomide

Thumbnail

D1.388 - Aspirin maintenance after boost with dupilumab in aspirin-exacerbated respiratory disease

Thumbnail

D1.389 - Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis Due to Allopurinol With Subsequent Sensitization to Brentuximab: A Case Report

Thumbnail

D1.390 - Hypersensitivity Reactions to Biological Agents in a Tertiary Hospital: A 3.5-Year Retrospective Study

Thumbnail

D1.392 - Drug-Induced Hypersensitivity Syndrome Associated with β-Lactams and Hemophagocytic Lymphohistiocytosis: Overlapping Disorders or a Causal Relationship?

Thumbnail

D1.393 - Safety of Aspirin Oral Provocation in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Thumbnail

- D1.532 - Phenotypic and Functional Comparison of LAD2, HMC-1.2, and Primary Human Mast Cells

Thumbnail

- D1.529 - Evaluating the Disease-Modifying Potential of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis: An Update on the Pivotal HARBOR Study

Thumbnail

- D1.530 - Patient Experience of Most Burdensome Nonadvanced Systemic Mastocytosis Symptoms From the Pivotal Summit Trial of Bezuclastinib

Thumbnail

- D1.531 - Avapritinib in Indolent Systemic Mastocytosis: Real-world Data from a Greek Case Series

Thumbnail

- D1.533 - Systemic mastocytosis despite normal baseline tryptase: a diagnostic pitfall in recurrent life-threatening anaphylaxis

Thumbnail

D3.464 - Influences of Climate and Environmental Exposures on Atopic Dermatitis Persistence and Asthma Development in Early Childhood: 6-Year Follow-up of Longitudinal Study